US$ 25.35
new glp 1 agonist novo nordisk Wegovy for the Treatment of Chronic Weight Management, US Novo Nordisk's oral GLP-1 drug
Description
J Clin Endocrinol Metab (2020) 105:295063
Furthermore, formal tests for publication bias, such as funnel plots or Eggers test, were not performed
doi: 10.1038/s42255-020-00327-x 16 ZhaoXWangMWenZLuZCuiLFuCet al

Yet realising this promising potential will depend on overcoming manufacturing and commercial challenges that are far from trivial

Online ahead of print
